If you’re taking a popular cholesterol-lowering drug to prevent heart attacks and stroke, I have news for you. It may not work for you – not if you’re a woman.
What’s more, the drug company that makes this drug knows this. But they don’t care. You see, it’s the biggest selling drug of its kind. It brings in $12 billion a year to Pfizer.
While this medication works pretty well for men, a recent meta-analysis completed by researchers at Cornell University and Cornell Law School found it does little for women. They could find no high-quality clinical evidence showing it reduces heart attacks in women.
What is this drug? Why, it’s Lipitor, of course.
None of the studies on Lipitor that included women showed statistically significant support for prescribing this statin to women.
Pfizer says the drug works for everyone. And the company sees nothing wrong with these claims. It’s just that they’re not backed up with good science. Pfizer has never reported that its drug works only for men.
In fact, it did just the opposite. It chose to mislead us with its advertising claims. Even its FDA-approved Lipitor label doesn’t mention this gender difference.
I’ve talked about the dangers of statins before in my newsletter. They rob your body of important nutrients like Coenzyme Q10 and they increase your risk for getting cancer.
Announcing a Pain-Relieving Formula Designed Especially for Aching Knees
Studies show it reduces pain and swelling, increases mobility, and even increases synovial fluid!
Click Here To Learn More
There are better and safer solutions to statins. You can find them on my database to all subscribers. One of them is policosanol, which has two advantages. It doesn’t deplete CoQ10 and it thins the blood, making aspirin and Coumadin unnecessary for many people.
Actually, it has three advantages. It works on women as well as on men.
Your voice of reason in Women's Health,
Dr. Janet Zand
Theodore Eisenberg and Martin T. Wells. “Statins and Adverse Cardiovascular Events in Moderate-Risk Females: A Statistical and Legal Analysis with Implications for FDA Preemption Claims.” Journal of Empirical Legal Studies, 2008; 5 (3).